

PATHELEN®

Hybrid

THE GOAL OF PATHELEN® HYBRID THERAPY (PHT)

PATHELEN® HYBRID is a hydrophobic/hydrophilic composition of fumed silica for topical application.

PHT adsorbs large volumes of wound exudate and pathogenic germs, thus reducing the bacterial load at the same time. This is achieved by dehydrating the treated wound surfaces. However, due to the specific ratio between hydrophilic and hydrophobic ingredients, the result is not excessive.

PATHELEN® HYBRID inhibits the formation of biofilms and pathogens, which have ideal growth conditions in moist wound areas.

PATHELEN® HYBRID prevents bandages/wound dressings from sticking to the wound surface. This ensures painless removal of the bandage/wound dressing.

Indications

- All kinds of topical wounds with wound exudates

Contraindications

- Don't apply on granulating wounds in the regeneration phase
- Don't apply on wounds with dry necrotic scab formation

Interaction with drugs

No interactions are known.

Warnings and precautions

Avoid eye contact. In case of contact, rinse eyes immediately with plenty of water and seek medical advice if necessary.

In case of irritation or intolerance do not continue to use the product, consult a doctor if necessary.

Keep out of reach of children.

Before first use, check that the safety cap is not broken or the bottle damaged. If this is the case, do not continue to use the product. Do not exceed the expiration date.

Preparation

Before starting a wound therapy with PATHELEN® HYBRID, the wound must be cleansed thoroughly. This is usually done with a classic debridement.

Application of PATHELEN® HYBRID

1. Removal of bandages, plasters etc.
2. Wound cleansing with an antiseptic solution, if necessary thorough debridement.
3. Drying of the wound surface e.g. with sterile swabs.
4. Shake a 60 ml bottle for about 10 seconds before application. The contents will retain the pseudo-liquid state only for a short time.
5. Immediately and carefully apply PATHELEN® HYBRID in an even layer of approx. 3 mm.
6. After application, dress the wound with sterile wound dressing.
7. Depending on the severity of the wound, further treatment should be repeated after 24-72 hours.
8. After granulation tissue has formed and epithelization has started, the PATHELEN® HYBRID treatment must be stopped and all further treatment should be continued with a moist sterile wound dressing until wound closure.

Maximum number of applications

PATHELEN® HYBRID can be used until the product is used up. There are no restrictions regarding the maximum number of applications prior to the formation of granulation tissue.

For children

Since PATHELEN® HYBRID is a non-systemic therapy and only acts on wound exudate, it can also be used to treat children.

Side effects

No allergies or side effects have been observed when using PATHELEN® HYBRID.

Shelf life

24 months (see manufacturing date on the label). After opening, please use within the shelf life. Storage: Please store in a cool, dry place, protected from direct sunlight and at temperatures not higher than 25°C / 77°F.

Packaging

Single packaging: 2 g powder in a 60 ml plastic bottle.

Clinical packing: 10 bottles of 2g in a cardboard.

INGREDIENTS :
Aerocel 300 Pharma 64.0%
Aerocel R972 Pharma 35.9%
Benzalkonium Chloride 0.1%

MEDICAL DEVICE CLASS I
Swissmedic Registration CH-201805-2
US FDA Registration 3017399130



PATHELEN HEALTH CARE AG

Hauptstrasse 65
9400 Rorschach
Switzerland
info@pathelen.com
www.pathelen.com

